Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Madrigal Pharmaceuticals Inc MDGL

Healthcare Biotechnology
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-ß (THR-ß) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic... see more

Recent & Breaking News (NDAQ:MDGL)

Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health

GlobeNewswire November 10, 2023

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

GlobeNewswire November 10, 2023

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results

GlobeNewswire November 6, 2023

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

GlobeNewswire November 2, 2023

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 12, 2023

Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering

GlobeNewswire September 28, 2023

Madrigal Pharmaceuticals Announces Proposed Public Offering

GlobeNewswire September 28, 2023

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 14, 2023

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis

GlobeNewswire September 13, 2023

Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer

GlobeNewswire September 11, 2023

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results

GlobeNewswire August 8, 2023

Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

GlobeNewswire July 17, 2023

Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

GlobeNewswire June 30, 2023

Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress(TM)

GlobeNewswire June 22, 2023

Madrigal Pharmaceuticals Supports International NASH Day on June 8

GlobeNewswire June 6, 2023

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

GlobeNewswire June 1, 2023

Madrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference

GlobeNewswire May 11, 2023

Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results

GlobeNewswire May 9, 2023

Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial

GlobeNewswire April 18, 2023

Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results

GlobeNewswire February 23, 2023